SCHEMBL10072925

SCHEMBL10072925

CC1CC(NS(=O)(=O)c2n[nH]c3ncccc23)CC(C)(C)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
NPSR1 Q6W5P4 1/20 0.50
TDP1 Q9NUW8 1/20 0.39
PAK1 Q13153 1/20 0.36
CFD P00746 1/20 0.35
HTT P42858 1/20 0.33
CNR2 P34972 1/20 0.32
CDC7 O00311 3/20 0.32
DAPK3 O43293 3/20 0.32
ROCK2 O75116 3/20 0.32
MAP4K4 O95819 3/20 0.32
PAK4 O96013 3/20 0.32
PRKACA P17612 3/20 0.32
CDK2 P24941 3/20 0.32
FLT3 P36888 3/20 0.32
CLK2 P49760 3/20 0.32
GSK3B P49841 3/20 0.32
CDK9 P50750 3/20 0.32
PRKX P51817 3/20 0.32
JAK3 P52333 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10073641 0.74 BRD4 (0.39) ALDH1A1CNR2CDC7DAPK3ROCK2
SCHEMBL13473561 0.73 JAK3 (0.32) CDC7DAPK3ROCK2MAP4K4PAK4
SCHEMBL10073166 0.72 APP (0.52) CNR2
SCHEMBL10073843 0.70 CNR2 (0.38) ALDH1A1CNR2
SCHEMBL10073651 0.69 FFAR2 (0.32) FFAR2
SCHEMBL12243451 0.69 ADAM17 (0.32)
SCHEMBL10072915 0.69
SCHEMBL10072900 0.69 HSD11B1 (0.52)
SCHEMBL12243475 0.68 MET (0.39) HTTGSK3BKMT2A
SCHEMBL10072893 0.68 ALDH1A1 (0.41) ALDH1A1JAK3KMT2AMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445681-B2 Azaindazoles useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-21 US disclosed
EP-2514751-A1 Azaindazoles useful as inhibitor of kinases Vertex Pharmaceuticals, Inc. (US) 2012-10-24 EP disclosed
US-20120165367-A1 AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES VERTEX PHARMACEUTICALS INCORPORATED 2012-06-28 US disclosed
US-8017781-B2 Azaindazoles useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-13 US disclosed
US-8017781-B2 Azaindazoles useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-13 US disclosed
US-20070179177-A1 Azaindazoles useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED 2007-08-02 US disclosed
US-20070179177-A1 Azaindazoles useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED 2007-08-02 US disclosed
WO-2007059219-A1 AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179177-A1 Azaindazoles useful as inhibitors of kinases PRKDC, MAP3K20, PRKACA ALDH1A1 3237/4885NPSR1 4485/4885TDP1 847/4885
US-20120165367-A1 AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES PRKDC, MAP3K20, PRKACA ALDH1A1 3237/4885NPSR1 4485/4885TDP1 847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.